# LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

> **NCT02159066** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 158 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** LGX818
- **DRUG:** MEK162
- **DRUG:** LEE011
- **DRUG:** BGJ398
- **DRUG:** BKM120
- **DRUG:** INC280

## Key facts

- **NCT ID:** NCT02159066
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-23
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02159066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02159066, "LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02159066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*